Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc at Jefferies Healthcare Conference Transcript

Jun 07, 2023 / 05:00PM GMT
Release Date Price: €32.2 (+3.21%)
Andrew Tsai
Jefferies LLC - Analyst

Hi, everyone. We're going to get started on our next session. I'm Andrew Tsai, senior biotech analyst here at Jefferies. And it's my pleasure to have Supernus joining us today. I have Jack Khattar, CEO. So welcome, Jack.

Jack Khattar
Supernus Pharmaceuticals, Inc. - President & CEO

Thank you. Thanks for having me.

Andrew Tsai
Jefferies LLC - Analyst

Jack, so for those in the audience who might be less familiar with Supernus, maybe give us a background about the company. Any opening remarks you'd like to make and then we can talk about catalysts to look forward to potentially in the next six or four months.

Jack Khattar
Supernus Pharmaceuticals, Inc. - President & CEO

Again, good afternoon, everyone. And thanks for coming here. Just a quick reminder, I will be making forward-looking statements, so please check the risk factors associated with the business in our SEC filings.

So as a very brief background for those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot